Scleroderma, also called systemic sclerosis when it affects internal organs, is a rare autoimmune connective tissue disease characterized by skin thickening, vascular dysfunction, and progressive fibrosis. Estimates suggest 75,000 to 100,000 Americans live with the disease, with women affected 4 to 5 times more often than men according to the NIAMS. Scleroderma’s reputation as one of the most challenging rheumatic diseases comes from its variable course — some patients live decades with stable skin disease, others develop life-threatening pulmonary or kidney complications within years of onset.
The Two Major Categories
Localized scleroderma affects skin and underlying tissues without significant internal organ involvement. Morphea (patches of thickened skin) and linear scleroderma (bands of skin tightening, sometimes affecting underlying muscle and bone) are the main subtypes. These forms are more common in children and rarely progress to systemic disease.
Systemic sclerosis affects skin plus internal organs and is itself divided into limited cutaneous (lcSSc, formerly called CREST syndrome) and diffuse cutaneous (dcSSc) forms. Limited disease shows skin thickening only on hands, forearms, face, and feet, with slow progression and high rates of pulmonary hypertension over time. Diffuse disease involves trunk and proximal limb skin, progresses faster, and carries higher early risk of interstitial lung disease and renal crisis.
Raynaud’s: Often the First Sign
Raynaud’s phenomenon — fingers turning white, then blue, then red in response to cold or stress — affects more than 95 percent of scleroderma patients and often precedes other symptoms by years. While Raynaud’s alone is common and usually benign (primary Raynaud’s), Raynaud’s accompanied by abnormal nailfold capillaries, autoantibodies, or skin changes points to scleroderma or another connective tissue disease.
Severe Raynaud’s in scleroderma can cause digital ulcers, gangrene, and finger amputation. Calcium channel blockers (nifedipine, amlodipine) are first-line. Phosphodiesterase-5 inhibitors (sildenafil, tadalafil) and prostacyclin analogs are added for severe or refractory disease per Cleveland Clinic guidance. Avoiding cold exposure, smoking cessation, and avoiding vasoconstrictor drugs all help.
Skin Changes
Skin thickening typically begins in the fingers (sclerodactyly) and may progress to the hands, forearms, face, and beyond. Early disease can include puffy hands and tendon friction rubs. As fibrosis progresses, skin becomes tight, shiny, and hyperpigmented, with telangiectasias on the face and hands.
Calcinosis — calcium deposits in the skin — affects about 25 percent of patients and can ulcerate painfully. The CREST acronym (Calcinosis, Raynaud’s, Esophageal dysmotility, Sclerodactyly, Telangiectasias) historically described limited cutaneous disease but is no longer formally used in classification.
Internal Organ Involvement
Esophageal dysmotility affects 70 to 90 percent of systemic sclerosis patients, producing reflux, dysphagia, and increased risk of Barrett’s esophagus. Proton pump inhibitors are typically used long term. Gastric antral vascular ectasia (watermelon stomach), small bowel bacterial overgrowth, and constipation from colonic dysmotility complicate the GI picture.
Interstitial lung disease (ILD) is the leading cause of disease-specific mortality. It affects roughly 40 to 50 percent of systemic sclerosis patients, with anti-Scl-70 (topoisomerase) antibodies marking elevated risk. Pulmonary function tests showing declining FVC and DLCO, plus high-resolution CT, guide diagnosis and monitoring.
Pulmonary arterial hypertension affects 8 to 12 percent of systemic sclerosis patients, more often the limited subtype, and develops over years. Annual screening with echocardiography and BNP is standard. Treatment uses endothelin receptor antagonists, PDE-5 inhibitors, and prostacyclin agonists.
Scleroderma renal crisis — severe hypertension and acute kidney injury — affects 10 to 15 percent of diffuse cutaneous patients, especially in the first 4 years and on corticosteroids over 15 mg daily. ACE inhibitors transformed outcomes from near-universal fatality to substantial recovery if recognized and treated promptly.
Diagnosis
The 2013 ACR/EULAR criteria assign points for various features. Skin thickening of fingers extending proximal to the metacarpophalangeal joints alone is sufficient for classification. Otherwise, points are summed from puffy fingers, sclerodactyly, fingertip lesions, telangiectasias, abnormal nailfold capillaries, lung involvement, Raynaud’s, and specific autoantibodies.
Autoantibody testing is central. Anti-centromere antibodies suggest limited disease and pulmonary hypertension risk; anti-Scl-70 (topoisomerase I) suggests diffuse disease and ILD risk; anti-RNA polymerase III suggests diffuse disease and renal crisis risk. Other antibodies (anti-U3 RNP, anti-Th/To, anti-PM-Scl) carry their own associations.
Modern Treatment Options
Treatment is organ-targeted because no single therapy controls all manifestations. For early diffuse skin disease, mycophenolate mofetil and methotrexate are commonly used. For ILD, mycophenolate, cyclophosphamide, nintedanib (an antifibrotic), and tocilizumab (an IL-6 inhibitor) all have evidence and FDA approval in this context.
Autologous hematopoietic stem cell transplant has produced durable benefit in carefully selected patients with severe progressive diffuse disease per PMC reviews. The procedure carries early mortality risk and is offered at specialized centers.
For pulmonary hypertension, combination targeted therapy (endothelin receptor antagonist plus PDE-5 inhibitor, with prostacyclin agonist for advanced disease) has improved survival substantially. For renal crisis, ACE inhibitors are continued indefinitely once initiated, even with worsening kidney function in the short term.
When to seek emergency care: Call 911 or go to the nearest emergency room if you experience sudden severe shortness of breath, blue lips or fingers, sudden severe headache with very high blood pressure (possible scleroderma renal crisis), severe chest pain, sudden severe abdominal pain, signs of digital gangrene (black painful fingertips), or signs of serious infection while on immunosuppressants. Renal crisis is a medical emergency where outcomes depend critically on prompt ACE inhibitor initiation.
Living With Scleroderma
Daily routines emphasize prevention. Cold exposure protection — gloves, hand warmers, layered clothing — reduces Raynaud’s. Skin care with regular moisturizers and gentle cleansers helps with dryness and tightness. Range-of-motion exercises preserve hand and finger function as fibrosis progresses.
Reflux management requires elevated head of bed, avoiding food 3 hours before lying down, weight management, and consistent PPI use. Small frequent meals help with dysmotility. Dental care matters because oral aperture narrowing and Sjögren’s-overlap dryness raise cavity risk.
Mental health support is important. Body image changes, fatigue, and the prognostic uncertainty of the disease all weigh on patients. Connecting with the Scleroderma Foundation and patient communities provides peer support that complements medical care. Our medical conditions overview and Sjögren’s syndrome guide cover related autoimmune disease management.
When to See a Doctor
New Raynaud’s phenomenon — especially in older adults, with finger ulcerations, with abnormal nailfold capillaries on physical exam, or with positive ANA — warrants rheumatology evaluation. New skin tightening, puffy fingers, or unexplained shortness of breath in a patient with known autoimmunity also justify prompt evaluation.
Established scleroderma patients need annual or semi-annual screening for ILD (pulmonary function tests), pulmonary hypertension (echocardiogram, BNP), and renal involvement (blood pressure, creatinine, urinalysis). Care is typically coordinated by rheumatology with input from pulmonology, cardiology, and gastroenterology as needed.
Frequently Asked Questions
Is scleroderma fatal?
It can be in severe systemic sclerosis with major organ involvement. Localized scleroderma is generally not life-shortening. Modern treatment of pulmonary hypertension, ILD, and renal crisis has significantly improved survival, but the disease remains one of the more serious connective tissue conditions.
What is the life expectancy with scleroderma?
Limited cutaneous systemic sclerosis has a near-normal life expectancy in many patients, while diffuse cutaneous disease with significant organ involvement has 10-year survival around 70 to 80 percent in modern cohorts. Outcomes have improved considerably with current therapies.
Is scleroderma hereditary?
Genetic susceptibility plays a role, but the disease is not directly inherited. First-degree relatives have a small increase in risk. Environmental triggers, including silica exposure and certain solvents, have been implicated in some cases.
Can scleroderma be cured?
There is no cure, but treatment has expanded significantly. Effective management of organ involvement, antifibrotic therapy for ILD, and stem cell transplant for severe disease can substantially alter the course. Patients have more options than ever, and outcomes continue to improve.
The Bottom Line
Scleroderma is a serious autoimmune disease where outcomes depend heavily on detecting and treating organ involvement before damage becomes irreversible. Routine screening for lung, heart, and kidney complications matters in every patient with systemic sclerosis. Modern targeted therapies — antifibrotics for ILD, pulmonary hypertension drugs, ACE inhibitors for renal crisis — have transformed the natural history. Connecting with a rheumatologist experienced in scleroderma, ideally at or in consultation with a specialized center, gives the best chance of long-term control. Patients who actively engage in monitoring and symptom management consistently do better than those who passively wait for problems to surface.